白云山公告,旗下白云山制药总厂获得国家药监局签发的枸橼酸西地那非片药品补充申请批准通知书,批准增加20mg规格并适用于治疗成人肺动脉高压,改善运动能力,延缓临床恶化。此外,桑菊感冒颗粒也获批变更说明书中安全性等内容。白云山制药总厂已在枸橼酸西地那非片研发项目上投入研发费用约776.94万元,在桑菊感冒颗粒研发项目上投入约10万元。本次补充申请的批准丰富了白云山的药品种类,有利于提升其市场竞争力,但...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.